Compulsory detention as drug treatment and the impact on HIV outcomes

Similar documents
HARM REDUCTION IN ASIA. Adeeba Kamarulzaman University of Malaya, Kuala Lumpur

Evidence from Compulsory Centres for Drug Users in East and South East Asia

KAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA

Opening Remarks. Second Regional Consultation on Compulsory Centres for Drug Users

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

The role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009

Place of addiction-informed comprehensive treatment in HIV care

Drug Use, Prisons and Compulsory Drug Treatment Centers

Opioid Withdrawal, Opioid Substitution, and HIV Infection

HIV AND PEOPLE WHO INJECT DRUGS

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1

Standards of Care Inventory (CARICOM)/DTC Luis Alfonzo Demand Reduction Specialist CICAD OAS

China Country Advocacy Brief Injecting Drug Use and HIV

support in Asia and the Pacific beyond For more details, see UNESCAP Resolutions: E/ESCAP/67/9 and E/ESCAP/66/10.

Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, Anand Grover

Continued in Part II (additional reading list at end of Part II)

ATLAS on substance use 2017:

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

COMMUNITY. Stigma and Discrimination Experienced by Sex Workers Living with HIV

Therapeutic Community within Community-Based Program for methamphetamine users in rural Thailand

Ending the AIDS epidemic by 2030

Opioid Withdrawal, Opioid Substitution, and HIV Infection

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

FACT SHEET 1 IRAN (ISLAMIC REPUBLIC OF)

Contents Opioid Treatment Program Core Program Standards... 2

Dr. dr. Diah Setia Utami, SpKJ, MARS Deputy of Rehabilitation Narcotic National Board of Republic of Indonesia

TB: INTEGRATION IN HARM REDUCTION PACKAGES. ICF "AIDS Foundation East-West (AFEW Ukraine) Tbilisi, 2015

Methadone Treatment. in federal prison

MYANMAR. Emerging trends and concerns

National Drug & Alcohol Treatment Policies & Standards in Jamaica MAY 19-20, 2015

Leaving no one behind in Asia and the Pacific. Steven J. Kraus Director UNAIDS Regional Support Team, Asia and the Pacific 28 th January 2015

The Global S.M.A.R.T. Programme: Synthetics Monitoring: Analysis, Reporting and Trends. ATS trends, programme progress and planned expansion

Part of the Continuum of Care. Harm Reduction. Gino Vumbaca President Harm Reduction Australia

Technical Briefs on amphetamine-type stimulants (ATS)

Methadone Treatment. in federal prison

Getting to zero HIV new infections in Asia and the Pacific region: Possible or impossible dream?

The new German strategy on HIV, Hepatitis B, C and STI, an integrated approach. Ines Perea Ministry of Health, Germany

Medication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford

Prof. Dr Heino Stöver Faculty of Health and Social Work University of Applied Sciences Frankfurt, Germany

Progress, challenges and the way forward in ASEAN Member States

State Opioid Response (SOR) Grant

People left behind: Sex workers

Substance Abuse Level of Care Criteria

PITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018

The Caring Center of Wichita LLC. General Information Client Name:

Myanmar United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific Baseline Assessment Dec 2006 ACRONYMS - MYANMAR

Briefing. Ending AIDS among people who use drugs Our theory of change

If so, when: Demographic Information Male Transgender Height: Weight: Massachusetts Resident? Primary Language: Are you currently homeless?

Models of good practice in drug treatment in Europe. Project group

Illicit manufacture of methamphetamine, primarily in pill form (yaba), continues, particularly in the Shan, Wa, and Kokang autonomous region.

Harm reduction in Asia: progress towards universal access to harm reduction services among people who inject drugs

What is harm reduction?

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story

Methadone Treatment as a Harm Reduction Strategy, Gender Sensitive Programming and Evidence-based Strategies

The Opioid Crisis: What Can Physicians Do About It?

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

The forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre

Presenters. Session Objectives. Session Overview. Cluster Investigations in Rural Wisconsin

Drug demand reduction and harm reduction: complementary approaches. Gilberto Gerra Chief Global Challenges Section Division for Operations

Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

Study Tour Report South-South Cooperation

FACT SHEET SERBIA (REPUBLIC OF)

Key Populations: Making Them Matter in the Global HIV Response Inextricable Links: HIV and Human Rights

Malaysia. Key Data Issues and Suggestions

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Pragmatic and Creative Responses to the Opioid Crisis in Connecticut

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Identifying Common Ground on Public Health for UNGASS 2016:

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

Opioids Research to Practice

Drug Policy and the HIV Movement. SAULIUS CAPLINSKAS MD, PhD

Tajikistan National Report. Summary HARM REDUCTION WORKS FUND IT! Arguments for strategic investment. Summary of National Report: Tajikistan

FACT SHEET TAJIKISTAN (REPUBLIC OF)

Children and Adults with Attention-Deficit/Hyperactivity Disorder Public Policy Agenda for Adults

*IN10 BIOPSYCHOSOCIAL ASSESSMENT*

The Netherlands Drug Situation Summary

GLOBAL AIDS MONITORING REPORT

More than 22,000 people have attended the programs of Dianova

Should buprenorphine be covered for maintenance treatment in opioid dependent persons?

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

APPLICATION FORM NAME:

Regional Dialogue Submissions

Monitoring HIV/AIDS Programs: Participant Guide

Harm Reduction in Nigeria

HIV in Prison Situation in Frankfurt am Main

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

HIV, drugs and the legal environment

Report of the 16 th. Core Group meeting Almaty, Kazakhstan May 26-28, 2010

Injecting Drug Users: A Global Problem. Roger Detels, M.D., M.S.

Adapting Treatment 2.0 in Viet Nam - Toward Universal and Sustainable Access -

MINISTRY OF HEALTH STRATEGIC FRAMEWORK OF COMMUNICATION FOR HIV/AIDS AND STIs INTRODUCTION

New London CARES Coordinated Access, Resources, Engagement and Support

Addressing HIV prevention, care, and research priorities among MSM in Asia

Drug Issues and Priorities for Southeast Asia: a UNODC Perspective

Drug Use, Harm Reduction, and HIP

State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment

Transcription:

Compulsory detention as drug treatment and the impact on HIV outcomes A Kamarulzaman, J McBrayer University of Malaya, Kuala Lumpur, Malaysia UNODC Scientific Event Science Addressing Drugs And Health: State of the Art 11 March 2014, Vienna, Austria

Over 1,000 compulsory centres across Asia Myanmar, Cambodia, China, Laos, Malaysia, Thailand, and Vietnam An estimated 400,000 PWUD detained in CCDU No of detainees range from 2000 210 000 depending on country Duration of detention varies form country to country

Administered through criminal or administrative law Operated by variety of institutions law enforcement authorities judiciary local/municipal authorities Ministry of Health and the Ministry of Social Affairs Admission typically extrajudicial, without due legal process Detained in police sweeps, single positive urine test, turned over by family or community members.

Treatment of Substance Use Substance use disorders highly prevalent Treatment - largely based on abstinence Rarely have trained professionals or medical staff Relapse rates 70% or more

Gruelling physical exercises Military style training Physical abuse and torture Denial of or inadequate provision of medical care Forced work regimens set within an abusive environment Variety of human rights abuses

Prevention and Treatment of HIV Data on HIV and HCV prevalence scarce No access to treatment for HIV and comorbidities Lack of financial resource Lack of trained staff General negative attitude towards PWUD

Prevention and Treatment of HIV Mandatory HIV testing common Detainees often not told of results No linkages to care No assessment of CD4

Sept 2012 July August 2010 28 Centres, 6,658 detainees 100 HIV +ve detainees in 2 Centres 70% from rural area Mean of 3.0 cumulative detentions in prison, 2.3 in CCDU 90 minute survey MINI, DAST-10, PHQ-9, TB symptom screening algorithm

95% met DSM-IV criteria for opioid dependence 93% reported substantial or high addiction severity prior to detention. 95% injected drugs in the 30 days prior to detention 65% reported daily heroin injection 22% reported daily injection of multiple substances

Life Time Use Alcohol 92 Heroin 99 Buprenophrine 47 Benzodiazepine 55 ATS 89 Ketamine 21 Cannabis 81 Multiple substances 91

78% had been diagnosed with HIV 20% during this detention Mean time since HIV diagnosis - 5.4 years 9% had received any HIV-related clinical assessment or care No access to ARV 34% had ever been CD4 tested 18% had ever received a CD4 test result Median CD4 count - 315 cells/ml (range 15 1025 cells/ml) ¾ were on ARV 30 days prior to detention - forced to discontinue treatment due to its unavailability in the detention facility

23% screened positive for symptoms indicative of active tuberculosis based on a screening algorithm (sensitivity 93%; specificity 36%) prolonged cough (65%), fever (56%) and night sweats (30%) 14% had suicidal ideation over the previous two weeks.

Dec 2008 In-depth and key informant interviews 19 PWID, 20 government and NGO officials Average drug use 14 y (range 8 23 y) Detox 4 times (range 1-8 times) Intense fear of being recognized by the police and being detained Routine HIV testing without consent and without disclosure of the result HIV-infected detainees were not routinely provided medical or drug dependency treatment IDUs received little or no information or means of HIV prevention

The impact of compulsory drug detention exposure on the avoidance of healthcare among injection drug users in Thailand 435 IDU 111 (25.5%) reported avoiding healthcare Avoiding healthcare associated with exposure to compulsory drug detention (adjusted prevalence ratio [APR] = 1.60; 95% [CI]: 1.16 2.21), having been refused healthcare (APR = 3.46; 95% CI: 2.61 4.60), experiencing shame associated with one s drug use (APR = 1.93; 95% CI: 1.21 3.09). IJDP 2014

Evolving response

Transformation of Compulsory Drug Detention Centers into Voluntary Evidence Based Treatment & Care Centers - Malaysia

CONCEPT OPEN ACCESS SERVICES Voluntarism or Walk-in Support from parents or family Referral Outreach / Motivate No Legal Implications No Pre-conditions No stigma Private and Confidential Options for clients Community-based Program Clients as patients

COMPULSORY DRUG REHAB. CENTERS Compulsory Treatment & Admission through the Law; Criminal Records; Stigma Treatment- psychosocial based services only C&C CLINIC Compulsory Treatment & Admission through the Law; Criminal Records; Stigma Focus on medical, psychiatric & clinical treatment Focus on medical, psychiatric & clinical treatment Treatment Duration 2 years Capacity for residents in DRCs 7,350 Cost of food RM8.00 x 30 days x 12 months /person = RM 2,880 Treatment for all substance abusers (opiate, ATS, inhalant) males, females & adolescent are separated Treatment duration 1-3 months (inpatient), 4-6 months (outpatient) Number of clients that accessed services at 8 C&C Clinics 9,041 Cost of food RM8.00 x 30 x 3 months = RM720.00 (able to treat 4x more no patients) Loss of Property caused by violence, arson No incidence of violence or arson

C&C 1MALAYSIA (C&C) & CURE&CARE REHAB CENTER (CCRC) Malaysia 2011-2013 year CCRC-Legal sanction (sek.6(1)(a) No of detainees C&C- Voluntary Cure & Care Centres No of clients 2011 4,789 9,376 2012 5,473 12,766 2013 5,136 14,426 TotaL 15,398 36,568 12 CCDU HAVE BEEN CONVERTED TO CURE & CARE CLINICS WITH REMAINING 18 STILL FUCTIONING CURRENTLY 6,500 CLIENTS ARE RECEIVING METHADONE AT ALL THESE VOLUTARY CENTRES

This significant change in policy signals a new sense of urgency. As drug dependency is a health issue that should be treated medically, there is a need to take a bolder but softer approach rather than a punitive one. This is why efforts must be stepped up to decriminalise drug dependency, actively address the issue of the stigma of addiction. NST March 2011

Challenges in moving towards a voluntary community-based treatment centres a. Laws of several countries providing for detention of people who use drugs in CCDUs; b. Stigma and discrimination c. Limited technical capacity for voluntary community-based drug treatment d. Imbalances between investments in supply and demand reduction

Key Recommendations Reviews of laws, policies and practices Reallocate human and financial resources from CCDUs to voluntary community-based treatment Mobilise additional human resources, including involvement of affected population Build capacity through specialized training for the delivery of voluntary community-based services.